Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate

PLoS Negl Trop Dis. 2024 May 20;18(5):e0012175. doi: 10.1371/journal.pntd.0012175. eCollection 2024 May.

Abstract

In Brazil, Leishmania amazonensis is the etiological agent of cutaneous and diffuse cutaneous leishmaniasis. The state of Maranhão in the Northeast of Brazil is prevalent for these clinical forms of the disease and also has high rates of HIV infection. Here, we characterized the drug susceptibility of a L. amazonensis clinical isolate from a 46-year-old man with diffuse cutaneous leishmaniasis coinfected with HIV from this endemic area. This patient underwent several therapeutic regimens with meglumine antimoniate, liposomal amphotericin B, and pentamidine, without success. In vitro susceptibility assays against promastigotes and intracellular amastigotes demonstrated that this isolate had low susceptibility to amphotericin B, when compared with the reference strain of this species that is considered susceptible to antileishmanial drugs. Additionally, we investigated whether the low in vitro susceptibility would affect the in vivo response to amphotericin B treatment. The drug was effective in reducing the lesion size and parasite burden in mice infected with the reference strain, whereas those infected with the clinical isolate and a resistant line (generated experimentally by stepwise selection) were refractory to amphotericin B treatment. To evaluate whether the isolate was intrinsically resistant to amphotericin B in animals, infected mice were treated with other drugs that had not been used in the treatment of the patient (miltefosine, paromomycin, and a combination of both). Our findings demonstrated that all drug schemes were able to reduce lesion size and parasite burden in animals infected with the clinical isolate, confirming the amphotericin B-resistance phenotype. These findings indicate that the treatment failure observed in the patient may be associated with amphotericin B resistance, and demonstrate the potential emergence of amphotericin B-resistant L. amazonensis isolates in an area of Brazil endemic for cutaneous leishmaniasis.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B* / pharmacology
  • Amphotericin B* / therapeutic use
  • Animals
  • Antiprotozoal Agents* / pharmacology
  • Antiprotozoal Agents* / therapeutic use
  • Brazil
  • Drug Resistance*
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • Humans
  • Leishmania / classification
  • Leishmania / drug effects
  • Leishmania / isolation & purification
  • Leishmania mexicana / drug effects
  • Leishmania mexicana / isolation & purification
  • Leishmaniasis, Cutaneous / drug therapy
  • Leishmaniasis, Cutaneous / parasitology
  • Leishmaniasis, Diffuse Cutaneous / drug therapy
  • Leishmaniasis, Diffuse Cutaneous / parasitology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Middle Aged
  • Parasitic Sensitivity Tests

Substances

  • Amphotericin B
  • Antiprotozoal Agents

Grants and funding

This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (grant number 2016/21171-6), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (grant number 405235/2021-6), and the Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão (FAPEMA) (UNIVERSAL-06726/22). ACC has also, in part, received funding from UK Research and Innovation via the Global Challenges Research Fund under grant agreement ‘A Global Network for Neglected Tropical Diseases’ (grant number MR/P027989/1). MISL was also supported by the PROCAD-Amazônia (grant number 001-21/2018) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (Finance code: 001). BAF, EMC, and SR were fellows supported by FAPESP (2020/01948-1, 2019/22175-3 and 2022/06176-2).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.